Pfizer (PFE): PT Jumps To $41 At Deutsche Bank

Deutsche Bank analyst, Gregg Gilbert, reiterated his Buy rating on shares of Pfizer (NYSE: PFE) and raised his price target to $41 from $38 on higher sales for Eliquis, Xeljanz, Lyrica, and Chantix.

The analyst also reduced his tax rate estimates from 23% to 21% and stated "PFE expects a lower rate from tax reform (the company plans to discuss specifics on its 4Q call). Our new 4Q17E EPS is $0.56 (from $0.55) and 2018E EPS is $2.76 (from $2.68)".

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $36.99 yesterday.

You May Also Be Interested In

• Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities
• Teradyne (TER) PT Raised to $125 at TD Cowen
• TechnipFMC (FTI) PT Raised to $30 at BTIG